Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors

Jayme L. Dahlin, Kathryn M. Nelson, Jessica M. Strasser, Dalia Barsyte-Lovejoy, Magdalena M. Szewczyk, Shawna Organ, Matthew Cuellar, Gurpreet Singh, Jonathan H. Shrimp, Nghi Nguyen, Jordan L. Meier, Cheryl H. Arrowsmith, Peter J. Brown, Jonathan B. Baell, Michael A. Walters

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

Many compounds with potentially reactive chemical motifs and poor physicochemical properties are published as selective modulators of biomolecules without sufficient validation and then propagated in the scientific literature as useful chemical probes. Several histone acetyltransferase (HAT) inhibitors with these liabilities are now routinely used to probe epigenetic pathways. We profile the most commonly used HAT inhibitors and confirm that the majority of them are nonselective interference compounds. Most (15 out of 23, 65%) of the inhibitors are flagged by ALARM NMR, an industry-developed counter-screen for promiscuous compounds. Biochemical counter-screens confirm that most of these compounds are either thiol-reactive or aggregators. Selectivity panels show many of these compounds modulate unrelated targets in vitro, while several also demonstrate nonspecific effects in cell assays. These data demonstrate the usefulness of performing counter-screens for bioassay promiscuity and assay interference, and raise caution about the utility of many widely used, but insufficiently validated, compounds employed in chemical biology.

Original languageEnglish (US)
Article number1527
JournalNature communications
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2017

Bibliographical note

Publisher Copyright:
© 2017 The Author(s).

Fingerprint

Dive into the research topics of 'Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors'. Together they form a unique fingerprint.

Cite this